Clinical Trials Browser

OTHER × Has results × Nivolumab × Clear all

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT03799445 2026-03-17

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Phase 2 Active not recruiting

37 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT02829918 2026-03-11

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Phase 2 Completed

54 enrolled 11 charts

Gastrointestinal

Biliary Tract Neoplasms, Digestive System Diseases

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Phase 2 Active not recruiting

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03370276 2026-03-10

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 1/2 Completed

95 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Melanoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2 Active not recruiting

14 enrolled 9 charts

Melanoma

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

8 enrolled 9 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04526730 2026-02-20

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Phase 2 Completed

17 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT02523469 2026-02-17

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1/2 Completed

67 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03388190 2026-02-13

METIMMOX

Phase 2 Completed

80 enrolled 13 charts

Neoplasm Metastasis, Neoplasms

NCT03785873 2026-02-13

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Completed

34 enrolled 13 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Phase 2 Completed

27 enrolled 9 charts

Uveal Melanoma

NCT03203473 2026-02-06

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Phase 2 Active not recruiting

85 enrolled 17 charts

Kidney Neoplasms

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast Neoplasms

NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Active not recruiting

30 enrolled 14 charts

Head and Neck Neoplasms

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 2 Active not recruiting

40 enrolled 14 charts

Meningioma

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Phase 1/2 Active not recruiting

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03829722 2026-01-22

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Phase 2 Completed

26 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT03285321 2026-01-20

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

39 enrolled 18 charts

Lung Neoplasms

NCT02656706 2026-01-16

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Phase 2 Active not recruiting

22 enrolled 10 charts

Melanoma

NCT03267498 2026-01-12

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Phase 2 Completed

40 enrolled 14 charts

Nasopharyngeal Carcinoma

NCT03425331 2026-01-08

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Phase 1 Active not recruiting

11 enrolled 11 charts

Melanoma

NCT03172624 2025-12-18

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Phase 2 Completed

64 enrolled 9 charts

Salivary Gland Neoplasms

NCT03347838 2025-12-12

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

Phase 2 Active not recruiting

19 enrolled 10 charts

Head & NeckOther neoplasm

Tobacco Smoking, Head and Neck Neoplasms, Precancerous Conditions

NCT02259621 2025-12-03

NA_00092076

Phase 2 Active not recruiting

39 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04021043 2025-12-03

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Phase 1/2 Completed

51 enrolled 16 charts

Neoplasm Metastasis

NCT02939300 2025-11-14

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Phase 2 Completed

18 enrolled 17 charts

Meningeal Carcinomatosis

NCT03021993 2025-11-12

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Phase 2 Completed

17 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT02823990 2025-11-10

TG4010 and Nivolumab in Patients With Lung Cancer

Phase 2 Completed

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03557359 2025-11-03

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Phase 2 Completed

35 enrolled 9 charts

Glioma, Recurrence

NCT04205409 2025-11-03

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2 Active not recruiting

20 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03016871 2025-10-20

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Phase 2 Active not recruiting

78 enrolled 15 charts

Hodgkin Disease

NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

Phase 2 Terminated

13 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03573947 2025-10-14

TOP1705

Phase 2 Completed

46 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03404960 2025-10-10

Parpvax

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03963518 2025-10-06

SURROGATE-ICI

631 enrolled 6 charts

Neoplasms

NCT03414684 2025-09-29

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

78 enrolled 46 charts

Breast Neoplasms

NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Phase 1/2 Completed

48 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

NCT04057365 2025-08-13

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Phase 2 Terminated

15 enrolled 8 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

2 enrolled 10 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT02681302 2025-07-25

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02553642 2025-07-22

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Phase 2 Completed

81 enrolled 12 charts

DermatologicGenitourinary

Urinary Bladder Neoplasms, Melanoma

NCT03547999 2025-07-22

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Phase 2 Terminated

17 enrolled 16 charts

Gastrointestinal

Fowlpox, Colorectal Neoplasms